Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 48,345 | 61,884 | 99,135 | 26,972 | 32,189 |
| Cost of Goods | 7,036 | 6,710 | 6,937 | 5,029 | 4,219 |
| Gross Profit | 41,309 | 55,174 | 92,198 | 21,943 | 27,970 |
| Operating Expenses | 52,541 | 49,837 | 46,722 | 41,340 | 51,508 |
| Operating Income | -11,196 | 6,047 | 46,413 | -19,368 | -23,319 |
| Other Income | 1,832 | 794 | 322 | 103 | 34 |
| Pre-tax Income | -9,364 | 6,841 | 46,735 | -19,265 | -23,285 |
| Income Tax | 2,906 | 2,380 | -177,358 | 716 | 1,925 |
| Net Income Continuous | -12,270 | 4,461 | 224,093 | -19,981 | -25,210 |
| Net Income | $-12,270 | $4,461 | $224,093 | $-19,981 | $-25,210 |
| EPS Basic Total Ops | -0.18 | 0.06 | 3.23 | -0.29 | -0.36 |
| EPS Basic Continuous Ops | -0.18 | 0.07 | 3.23 | -0.29 | -0.36 |
| EPS Diluted Total Ops | -0.18 | 0.07 | 3.18 | -0.29 | -0.36 |
| EPS Diluted Continuous Ops | -0.18 | 0.08 | 3.18 | -0.29 | -0.36 |
| EBITDA(a) | $-10,600 | $6,649 | $46,906 | $-18,717 | $-22,663 |